Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Unresectable, Recurrent or Metastatic Tumors

NCT05270213 is registered in ClinicalTrials.gov with Riboscience, LLC. as lead sponsor.

NCT NCT05270213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05270213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Unresectable, Recurrent or Metastatic Tumors
Lead sponsor
Riboscience, LLC.
Phase
Phase 1
Overall status
Recruiting
Start date
July 11, 2022
Completion date
December 31, 2027
Enrollment
164 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer